The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
Sponsored by National Taiwan University Hospital
About this trial
Last updated 11 years ago
Study ID
URIC
Status
Unknown status
Type
Observational
Placebo
No
Accepting
20+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 12 years ago
What is this trial about?
Patients with hyperuricemia were confirmed to have higher risks of cardiovascular disease,
but the exact mechanism remained to be elucidated. Many connective tissue diseases such as
rheumatoid arthritis are often associated with antiphospholipid antibodies-associated
endothelial impairment. In the present study, the investigators will analyze the presence of
antiphospholipid antibodies in the serum of the patients with gout/asymptomatic
hyperuricemia, with a comparison to the patients of osteoarthritis but without hyperuricemia
and gout. The investigators expect to find a correlation between these pathogenic antibody
and those cardiovascular co-morbidities.
What are the participation requirements?
Inclusion Criteria
1. Patient with gouty arthritis
2. Patient with asymptomatic hyperurecemia
3. Patient of osteoarthritis but without hyperuricemia and gout